Reuters logo
BRIEF-Biotie Therapies Oyj updates outlook on Tozadenant and SYN120
July 30, 2014 / 6:40 AM / 3 years ago

BRIEF-Biotie Therapies Oyj updates outlook on Tozadenant and SYN120

July 30 (Reuters) - Biotie Therapies Oyj : * Biotie updates outlook on Tozadenant and SYN120 * Says Tozadenant to advance into phase 3 in Parkinson’s disease within

Biotie’s proprietary portfolio * Says considers Tozadenant to potentially be its most valuable asset * Evaluates options, which may include capital increase, to support clinical

studies and regulatory filing package for Tozadenant * Says previously planned phase 2 study in Alzheimer’s disease will not begin

recruitment by the end of 2014 * Says phase 2 study in Alzheimer’s disease will be assessed based on

development status of other products within portfolio * Source text for Eikon * Further company coverage

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below